President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and ...

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...

Novo Nordisk A/S (NVO) stock saw a modest uptick, ending the day at $85.64 which represents a slight increase of $2.30 or 2.76% from the prior close of $83.34. The stock opened at $85.51 and touched a ...

The company plans to create a new category of cellular medicines offering functional cures for metabolic and endocrine ...

President-elect Donald Trump threatened Tuesday to place new tariffs on imports from Denmark unless the country gives up control of Greenland, news that dented the stocks of some of Denmark's most ...

Brown-Forman's stock is a compelling investment with stable revenue and profit margins. Learn why BF.B is a Buy.

Aspect Biosystems raises US$115 million in Series B funding to advance multiple bioprinted tissue therapeutics towards the ...

Novo Nordisk said an agreement reached last year with privately held Lexington, Mass. company Valo Health that initially was valued at up to $2.7 billion is now been expanded to a $4.6 billion deal.

Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics ...

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...